Abstract
Psoriasis, a common, chronic, relapsing, inflammatory skin disease characterised by multiple erythematous papules and plaques with silvery scales, affects 0.5–3% of the world's population. Recently, great advances have been made in the treatment of psoriasis, including the introduction of targeted biological agents.1 However, topical treatment remains important; most patients have mild disease affecting less than 2% of the body surface area.2
This article is protected by copyright. All rights reserved.
http://ift.tt/2t2IyR3
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου